{"entity":{"id":"nuclide-therapeutics","kind":"company","name":"Nuclide Therapeutics","aka":["Nuclide Tx"],"tldr":"Nuclide Therapeutics is a UK start-up developing radioactive drugs for cancers that have stopped responding to other treatments. Its lead medicine carries radioactive iodine and was moving towards first human trials in 2026.","summary":"Nuclide Therapeutics is a UK company co-founded by Muhammet Tanç (CEO), Tim Witney (CSO), Sofia Santos (COO) and Richard Edwards (CTO), developing targeted radiotheranostics for therapy-resistant solid tumours. Its lead therapeutic, NTx-11, is labelled with iodine-131. The company announced a GBP 5 million investment in September 2025 to fund first-in-human trials, and an October 2025 release describes it as a milestone-based first investment round funded by Marathon Beteiligungs AG. Its pipeline lists NTx-010, NTx-011 and NTx-043 across diagnostic and therapeutic uses, from discovery to phase 0/1. In 2026 it announced a discovery collaboration using Enamine's platform and a co-development agreement with pharmAI, and Chemical & Engineering News named it one of ten start-ups to watch.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://nuclidetx.com/"},{"label":"Launch announcement","url":"https://nuclidetx.com/news/launch-announcement"},{"label":"Funding round press release","url":"https://nuclidetx.com/news/latest-press-release"},{"label":"Enamine collaboration release","url":"https://enamine.net/news-press-releases/press-releases/enamines-idd-platform-accelerates-nuclide-therapeutics-precision-radiotheranostics-pipeline-towards-the-clinic"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["radioligand-therapy","radioiodine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated by the company; third-party profiles say it was founded in 2024 as a spin-out of Tim Witney's lab at King's College London. Third-party sources name ALDH1A1 as the lead target, but the company site does not, so no target is linked. The website gives no city; London is from the Enamine release dateline and trade directories."],"hq":"London","country":"GB","companyType":"radiopharma","website":"https://nuclidetx.com/","stage":"startup","investors":[],"funding":[{"round":"Seed","year":2025,"source":"https://nuclidetx.com/news/latest-press-release","note":"GBP 5 million milestone-based first investment round funded by Marathon Beteiligungs AG; the company gives no USD figure. 'Seed' is the label used by trade databases."}]},"route":"/companies/nuclide-therapeutics/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}]}}